Compare AbCellera Biologics Inc (ABCL) vs Bill.com Holdings Inc (BILL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Bill.com Holdings Inc — how do they compare? AbCellera Biologics Inc trades at $7.15 (market cap $2.35B), while Bill.com Holdings Inc trades at $39.58 (market cap $4.05B). The key difference: Bill.com Holdings Inc is the larger of the two by market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Bill.com Holdings Inc nearer its low. Which is the better fit depends on your goals.
| ABCL | BILL | |
|---|---|---|
Market Cap | $2.35B | $4.05B |
Sector | Health | Technology |
52-Week High | $8.12 | $56.32 |
52-Week Low | $2.78 | $31.96 |
Enterprise Value | $1.99B | $3.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
BILL Holdings trades at $40.68, up 0.49% today, with strong analyst consensus pointing to a $48 price target. The stock shows bullish technical momentum with recent earnings beats and revenue growth from $1.3B to $1.46B in 2025. Recent executive appointments and AI focus signal strategic positioning for growth.
Outlook remains positive with 56% analyst buy ratings and 36% upside potential, though high P/E of 214 and thin net margins of 0.01% pose valuation risks. Key catalysts include continued earnings outperformance and AI integration, while macroeconomic sensitivity and competitive pressures require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Bill.com Holdings Inc
Bill.com Holdings Inc is a provider of cloud-based software that simplifies, digitizes, and automates financial operations for SMBs. Its artificial-intelligence enabled financial software platform used mostly to build connections between customers, suppliers, and clients. The company's platform generates and process invoices, streamline approvals, send and receive payments, sync with their accounting system, and manage their cash. The firm generates revenue through subscription and transaction fees.
Read more on BILL →
